September 1, 2015 -University Health Network’s (UHN) annual Inventor of the Year award
This year, the award was presented to Dr. Ralph DaCosta, Founder, Director and Chief Scientific Officer of MolecuLight Inc., for developing a handheld fluorescence-enabled imaging platform which allows instantaneous visualization of bacteria and tissues (in wounds) based on autofluorescence imaging
… Read MoreSeptember 1, 2015 -Advancing wound care and strengthening Ontario’s role as a global innovation leader in health care
Ontario healthcare innovator, MolecuLight Inc., is developing a hand-held optical imaging technology designed to visualize bacteria in real-time at the point-of-care. Founded by Dr. Ralph DaCosta, Scientist at The Princess Margaret Cancer Centre and Techna Institute
… Read MoreJune 26, 2015 -MolecuLight attended the Military Health System Research Symposium
MolecuLight attended the Military Health System Research Symposium (MHSRS) in Fort Lauderdale, FL which took place on August 18-21, 2014.
MHSRS is an annual event which provides an academic setting for new scientific knowledge arising from military specific research. This was a
… Read MoreJune 25, 2015 -Enabled better detection of otherwise subclinical bacterial colonization in surgical sites
At MHSRS (Military Health Science Research Symposium, 2014) a study was presented examining the effectiveness of the MolecuLight i:X for detecting subclinical bacterial contamination and guiding antimicrobial wound treatments. Handheld fluorescence imaging, used adjunctively with standard clinical signs and
… Read MoreMarch 26, 2015 -Real-time autofluorescence imaging of bacteria in diabetic foot ulcer patients
The publication describes two single-center, non-randomized trials that assessed the use for real-time autofluorescence imaging of bacteria in diabetic foot ulcer patients.
Click here to read full article. Read MoreNovember 28, 2014 -This important financial support will allow MolecuLight to accelerate commercialization
This important financial support will allow MolecuLight to accelerate commercialization of its unique patented handheld fluorescence-imaging platform, which will enable clinicians to detect bacteria in chronic wounds, in real-time and at the point-of-care. MolecuLight’s technology addresses an important problem in
… Read MoreNovember 7, 2014 -
Posted on November 07 , 2014
MolecuLight Inc. (Toronto, Canada) announced today a multi-project based research agreement with the University Health Network (UHN, Toronto, Canada) aimed at advancing their new handheld optical imaging technology enabling real-time bacterial imaging in wounds at the point-of-care.
Under the terms of the Agreement, MolecuLight Inc. will
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2025
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.